TL;DR
This study uncovers a novel mechanism by which YAP/TAZ proteins, known regulators of cell growth, act as a "brake" on the development of beige fat, a crucial metabolic tissue. By inhibiting the expression of the neurotrophic factor S100B, YAP/TAZ suppress the sympathetic innervation of beige fat. Loss of YAP/TAZ function in adipocytes leads to increased S100B, enhanced innervation, and improved metabolic health, offering potential therapeutic avenues for obesity and metabolic disorders.
What Problem Does This Paper Address?
Functional beige fat is vital for maintaining body temperature and metabolic homeostasis, playing a key role in energy expenditure and glucose/lipid metabolism. While sympathetic innervation is known to be essential for beige fat development and function, the precise molecular mechanisms controlling this innervation have remained largely elusive. This paper aims to elucidate these mechanisms, specifically focusing on how adipocytes themselves might regulate the sympathetic nervous system's interaction with beige fat. Understanding this regulation is critical for developing strategies to combat metabolic diseases like obesity, which are often associated with impaired beige fat function.
Methods
The researchers employed a multi-faceted approach:
- Genetic Manipulation: They used conditional knockout mouse models (e.g., adipocyte-specific deletion of Yap/Taz) to investigate the role of these proteins in beige fat.
- Molecular Biology Techniques: Co-immunoprecipitation (co-IP) and Cut&Tag assays were used to confirm protein-protein interactions and DNA binding, respectively. Western blotting and RT-qPCR were standard for assessing protein and mRNA expression levels.
- RNA Sequencing (RNA-seq): Bulk RNA-seq was performed on adipose tissue to identify differentially expressed genes and enriched pathways upon Yap/Taz deletion.
- Histology and Imaging: Hematoxylin and Eosin (H&E) staining was used to visualize tissue morphology, while whole-mount immunostaining (e.g., for tyrosine hydroxylase, TH, a marker of sympathetic nerves) and 3D imaging were employed to assess sympathetic innervation density and length.
- Metabolic Assays: Glucose tolerance tests (GTT) and insulin tolerance tests (ITT) were conducted to evaluate metabolic health. Oxygen consumption and respiratory exchange ratio (RER) were measured to assess energy expenditure.
- Viral Vector Delivery: Adeno-associated viruses (AAVs) were used for targeted overexpression or knockdown of genes (e.g., S100B, Yap/Taz) in specific tissues.
Datasets
- RNA-seq Data: Gene expression data from subcutaneous white adipose tissue (scWAT) of Yap/Taz knockout (YT-AKO) and control (YT-FF) mice was generated and analyzed.
- ChIP-seq Data: Publicly available ChIP-seq data for PRDM16 (GSE63965) and C/EBPβ (GSM686970) were utilized to identify binding sites on the S100B promoter.
- Human WAT RNA-seq Data: Publicly available RNA-seq data from human visceral WAT (vWAT) of lean and obese individuals (GSE141432) and GTEx database data were analyzed to assess S100B, YAP/TAZ, PRDM16, and C/EBPβ expression in different metabolic states.
Key Insights and Ideas
- YAP/TAZ as Inhibitors of Beige Fat Innervation: The most striking finding is that YAP/TAZ, typically associated with promoting cell growth and proliferation, actively inhibit the sympathetic innervation of beige fat. This is a counterintuitive role for these well-known transcriptional co-activators.
- The S100B Axis: YAP/TAZ exert their inhibitory effect by repressing the expression of S100B, a neurotrophic factor that is crucial for stimulating sympathetic innervation. This establishes a clear YAP/TAZ-S100B signaling axis.
- PRDM16 as a Central Mediator: PRDM16, a known regulator of beige fat biogenesis, is shown to interact with both YAP/TAZ and C/EBPβ. YAP/TAZ interfere with the PRDM16-C/EBPβ complex formation, thereby suppressing S100B transcription.
- Cold Exposure and Adrenergic Signaling: Cold-induced adrenergic signaling (via NE and PKA) inactivates YAP/TAZ by promoting their phosphorylation and nuclear exclusion. This release of YAP/TAZ inhibition allows for PRDM16-C/EBPβ complex formation, leading to increased S100B expression and enhanced sympathetic innervation.
- Visceral WAT Potential: The study highlights that YAP/TAZ also play a role in visceral WAT (eWAT), which is typically less responsive to browning. Loss of YAP/TAZ in eWAT can induce beige fat biogenesis and improve its metabolic function, suggesting eWAT could be therapeutically targeted.
Key Results
- Adipocyte-specific Yap/Taz deletion in mice led to increased expression of thermogenic genes (e.g., Ucp1, Elovl3) in scWAT, enhanced beige fat biogenesis, and improved energy expenditure, evidenced by higher oxygen consumption and core body temperature during cold exposure.
- YT-AKO mice exhibited significantly denser sympathetic innervation in scWAT compared to controls.
- S100B expression was significantly upregulated in scWAT of YT-AKO mice, and this upregulation was specifically observed in mature adipocytes.
- Overexpression of S100B in scWAT robustly induced beige fat biogenesis and thermogenic gene expression, mimicking the effects of Yap/Taz loss.
- YAP/TAZ directly interact with PRDM16 through its zinc finger-2 domain and compete with C/EBPβ for binding, thereby disrupting the PRDM16-C/EBPβ complex.
- Loss of Yap/Taz in adipocytes protected mice from age-associated and diet-induced obesity, leading to reduced fat mass, improved insulin sensitivity, and enhanced energy expenditure.
- AAV-mediated S100B administration in visceral WAT of obese mice restrained diet-induced obesity and improved glucose homeostasis, demonstrating therapeutic potential.
Limitations and Future Work
- BAT vs. WAT: The study observed no induction of thermogenic genes in brown adipose tissue (BAT) of YT-AKO mice. The authors attribute this to BAT having more PRDM16 and less active YAP/TAZ, making YAP/TAZ less effective in competing for C/EBPβ association. Future work could explore compensatory mechanisms in BAT.
- Neurological Symptoms: The YT-UKO mice (Ucp1Cre-mediated Yap/Taz deletion in BAT) exhibited abnormal circling behavior, suggesting potential off-target effects or a role of YAP/TAZ in the central nervous system that warrants further investigation.
- TEADs-binding Independence: While YAP/TAZ regulate S100B expression, the study indicates this regulation is TEADs-binding-independent, suggesting alternative interaction partners or mechanisms are at play.
- Therapeutic Translation: While S100B administration showed promise, further research is needed to optimize delivery methods and assess long-term efficacy and safety in more complex models. The study suggests targeting the YAP/TAZ-S100B axis as a therapeutic strategy for obesity and metabolic disorders, and potentially for cancer, given the role of YAP/TAZ in tumorigenesis.
Summary updated